BACKGROUND: Initial clinical trials from Europe have demonstrated that the administration of bone marrow-derived mononuclear cells (BMCs) may improve left ventricular (LV) function in patients following ST-elevation myocardial infarction (STEMI). However, results from trials performed in the United States have not yet been presented. METHODS: We developed a phase 1, randomized, placebo-controlled, double-blind trial to investigate the effects of BMC administration in patients following STEMI on recovery of LV function using cardiac magnetic resonance imaging (cMRI). Forty patients with moderate to large anterior STEMIs were randomized to 100 million intracoronary BMCs versus placebo 3 to 10 days following successful primary angioplasty and stenting (percutaneous coronary intervention) of the left anterior descending coronary artery. RESULTS: Administration of BMC was safely performed in a high-risk cohort with minimal major adverse clinical event rates, and all patients remain alive to date. Left ventricular ejection fraction increased from 49.0% +/- 9.5% at baseline to 55.2% +/- 9.8% at 6 months by cMRI in the BMC group (P < .05), which was not different from the increase in the placebo group (48.6% +/- 8.5% to 57.0% +/- 13.4%, P < .05). Left ventricular end-diastolic volume decreased by 4 mL/m(2) in the BMC group at 6 months but increased significantly in the placebo group (17 mL/m(2), P < .01). CONCLUSIONS: This phase 1 study from the United States confirms the ongoing safety profile of BMC administration in patients following STEMI. The improvement in LV ejection fraction at 6 months by cMRI in the cell therapy group was not different than the placebo group. However, BMC administration had a favorable effect on LV remodeling at 6 months. 2010 Mosby, Inc. All rights reserved.
RCT Entities:
BACKGROUND: Initial clinical trials from Europe have demonstrated that the administration of bone marrow-derived mononuclear cells (BMCs) may improve left ventricular (LV) function in patients following ST-elevation myocardial infarction (STEMI). However, results from trials performed in the United States have not yet been presented. METHODS: We developed a phase 1, randomized, placebo-controlled, double-blind trial to investigate the effects of BMC administration in patients following STEMI on recovery of LV function using cardiac magnetic resonance imaging (cMRI). Forty patients with moderate to large anterior STEMIs were randomized to 100 million intracoronary BMCs versus placebo 3 to 10 days following successful primary angioplasty and stenting (percutaneous coronary intervention) of the left anterior descending coronary artery. RESULTS: Administration of BMC was safely performed in a high-risk cohort with minimal major adverse clinical event rates, and all patients remain alive to date. Left ventricular ejection fraction increased from 49.0% +/- 9.5% at baseline to 55.2% +/- 9.8% at 6 months by cMRI in the BMC group (P < .05), which was not different from the increase in the placebo group (48.6% +/- 8.5% to 57.0% +/- 13.4%, P < .05). Left ventricular end-diastolic volume decreased by 4 mL/m(2) in the BMC group at 6 months but increased significantly in the placebo group (17 mL/m(2), P < .01). CONCLUSIONS: This phase 1 study from the United States confirms the ongoing safety profile of BMC administration in patients following STEMI. The improvement in LV ejection fraction at 6 months by cMRI in the cell therapy group was not different than the placebo group. However, BMC administration had a favorable effect on LV remodeling at 6 months. 2010 Mosby, Inc. All rights reserved.
Authors: Kai C Wollert; Gerd P Meyer; Joachim Lotz; Stefanie Ringes-Lichtenberg; Peter Lippolt; Christiane Breidenbach; Stephanie Fichtner; Thomas Korte; Burkhard Hornig; Diethelm Messinger; Lubomir Arseniev; Bernd Hertenstein; Arnold Ganser; Helmut Drexler Journal: Lancet Date: 2004 Jul 10-16 Impact factor: 79.321
Authors: Jacob Lønborg; Henning Kelbaek; Niels Vejlstrup; Erik Jørgensen; Steffen Helqvist; Kari Saunamäki; Peter Clemmensen; Lene Holmvang; Marek Treiman; Jan S Jensen; Thomas Engstrøm Journal: Circ Cardiovasc Interv Date: 2010-01-26 Impact factor: 6.546
Authors: Gerd P Meyer; Kai C Wollert; Joachim Lotz; Jan Steffens; Peter Lippolt; Stephanie Fichtner; Hartmut Hecker; Arnd Schaefer; Lubomir Arseniev; Bernd Hertenstein; Arnold Ganser; Helmut Drexler Journal: Circulation Date: 2006-03-06 Impact factor: 29.690
Authors: Stefan Janssens; Christophe Dubois; Jan Bogaert; Koen Theunissen; Christophe Deroose; Walter Desmet; Maria Kalantzi; Lieven Herbots; Peter Sinnaeve; Joseph Dens; Johan Maertens; Frank Rademakers; Steven Dymarkowski; Olivier Gheysens; Johan Van Cleemput; Guy Bormans; Johan Nuyts; Ann Belmans; Luc Mortelmans; Marc Boogaerts; Frans Van de Werf Journal: Lancet Date: 2006-01-14 Impact factor: 79.321
Authors: Ketil Lunde; Svein Solheim; Svend Aakhus; Harald Arnesen; Michael Abdelnoor; Torstein Egeland; Knut Endresen; Arnfinn Ilebekk; Arild Mangschau; Jan G Fjeld; Hans Jørgen Smith; Eli Taraldsrud; Haakon Kiil Grøgaard; Reidar Bjørnerheim; Magne Brekke; Carl Müller; Einar Hopp; Asgrimur Ragnarsson; Jan E Brinchmann; Kolbjørn Forfang Journal: N Engl J Med Date: 2006-09-21 Impact factor: 91.245
Authors: Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher Journal: N Engl J Med Date: 2006-09-21 Impact factor: 91.245
Authors: D Orlic; J Kajstura; S Chimenti; I Jakoniuk; S M Anderson; B Li; J Pickel; R McKay; B Nadal-Ginard; D M Bodine; A Leri; P Anversa Journal: Nature Date: 2001-04-05 Impact factor: 49.962
Authors: R A Kloner; T Shook; K Przyklenk; V G Davis; L Junio; R V Matthews; S Burstein; M Gibson; W K Poole; C P Cannon Journal: Circulation Date: 1995-01-01 Impact factor: 29.690
Authors: Ronak Delewi; Alexander Hirsch; Jan G Tijssen; Volker Schächinger; Wojciech Wojakowski; Jérôme Roncalli; Svend Aakhus; Sandra Erbs; Birgit Assmus; Michal Tendera; R Goekmen Turan; Roberto Corti; Tim Henry; Patricia Lemarchand; Ketil Lunde; Feng Cao; Heikki V Huikuri; Daniel Sürder; Robert D Simari; Stefan Janssens; Kai C Wollert; Michal Plewka; Stefan Grajek; Jay H Traverse; Felix Zijlstra; Jan J Piek Journal: Eur Heart J Date: 2013-09-11 Impact factor: 29.983
Authors: Rachel E Olson; Rachel W Vojvodic; Judy Bettencourt; Eileen M Handberg; Elizabeth Szymanski; Deirdre Smith; Jody LaRock; Shreela V Sharma; Doris A Taylor; Timothy D Henry Journal: Clin Res (Alex) Date: 2014-08
Authors: Vinodh Jeevanantham; Matthew Butler; Andre Saad; Ahmed Abdel-Latif; Ewa K Zuba-Surma; Buddhadeb Dawn Journal: Circulation Date: 2012-06-22 Impact factor: 29.690